Therapeutic DNA vaccine encoding HPV16 E6/E7 antigens that targets antigen-presenting cells to enhance cross-presentation and prime HPV16-specific CD8+ cytotoxic and CD4+ helper T-cell responses.
Plasmid DNA therapeutic vaccine encoding HPV16 E6/E7 fused to an APC‑targeting unit. Following intramuscular delivery, the plasmid drives expression of E6/E7 and an APC‑binding protein, promoting APC uptake, maturation, and cross-presentation on MHC I/II, thereby priming HPV16‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses to lyse HPV16 E6/E7–expressing tumor cells.
NO
INDIRECT
The vaccine binds receptors on antigen-presenting cells to deliver HPV16 E6/E7 for cross-presentation and APC activation, inducing HPV16-specific cytotoxic T cells that kill HPV16 E6/E7–positive tumor cells, not the APCs expressing the targeted receptor.
Humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1); activates NK cells via SLAMF7 and engages Fc gamma receptors to mediate ADCC against SLAMF7-positive myeloma cells.
Humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1). It activates NK cells via SLAMF7 signaling and engages Fc gamma receptors to mediate antibody-dependent cellular cytotoxicity (ADCC) against SLAMF7-positive myeloma cells.
YES
DIRECT
Elotuzumab binds SLAMF7 on myeloma cells and its Fc engages Fcγ receptors on NK cells to trigger antibody‑dependent cellular cytotoxicity (ADCC); it also activates NK cells via SLAMF7, enhancing killing.
Humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1); activates NK cells via SLAMF7 and engages Fc gamma receptors to mediate ADCC against SLAMF7-positive myeloma cells.
Humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1). It activates NK cells via SLAMF7 signaling and engages Fc gamma receptors to mediate antibody-dependent cellular cytotoxicity (ADCC) against SLAMF7-positive myeloma cells.
NO
INDIRECT
Elotuzumab’s Fc engages CD16A on NK cells to trigger ADCC against SLAMF7-positive tumor cells; CD16A-expressing cells act as effectors and are not killed.
A HER2-targeted antibody–drug conjugate composed of a monoclonal antibody linked to the microtubule inhibitor MMAE (vedotin). It binds HER2 (including HER2-low), is internalized, and releases MMAE to disrupt microtubules causing mitotic arrest and apoptosis; Fc-mediated ADCC may also contribute.
HER2-directed antibody–drug conjugate that binds HER2 (including HER2-low), is internalized, and releases the microtubule inhibitor MMAE (vedotin) to disrupt tubulin polymerization, causing microtubule disruption, mitotic arrest, and apoptosis; Fc effector function may also mediate ADCC.
YES
DIRECT
The ADC binds HER2 on target cells, is internalized, and releases MMAE, which disrupts microtubules to cause mitotic arrest and apoptosis; Fc effector function can also trigger ADCC.
A HER2-targeted antibody–drug conjugate composed of a monoclonal antibody linked to the microtubule inhibitor MMAE (vedotin). It binds HER2 (including HER2-low), is internalized, and releases MMAE to disrupt microtubules causing mitotic arrest and apoptosis; Fc-mediated ADCC may also contribute.
HER2-directed antibody–drug conjugate that binds HER2 (including HER2-low), is internalized, and releases the microtubule inhibitor MMAE (vedotin) to disrupt tubulin polymerization, causing microtubule disruption, mitotic arrest, and apoptosis; Fc effector function may also mediate ADCC.
NO
INDIRECT
The ADC binds HER2 (not beta-tubulin), is internalized, and releases MMAE that binds the vinca site on beta-tubulin to disrupt microtubules and trigger apoptosis; Fc-mediated ADCC may also contribute.